SunGlow Innovations
Development
Three independent programs across human and veterinary research.
United States · Human
Phase 1 planning
United States · Veterinary
Investigational development
China · Human
Application supplementation
IND 184255
United States · Human
SunGlow Innovations LLC is preparing an early clinical study of CDX-101 in adults with advanced extracranial solid tumors.
FDA pre-IND written feedback
Documented development milestone
Original IND receipt date recorded by FDA
Documented development milestone
Protocol v3.0 and responses to clinical and clinical pharmacology comments prepared in sequence 0006
Phase 1 planning
U.S. FDA clinical development timeline
The U.S. and China programs advance in parallel. Enrollment, follow-up and preparation for the next stage are planned together to maintain continuity.
50+Cumulative enrollment target
-
2026–2027
Phase 1 start-up and early enrollment
Use the U.S. IND protocol to open the safety lead-in and track safety and response from the first participant.
-
2027
Sequential enrollment and expansion
Continue the U.S. development program toward at least 50 cumulative participants, with follow-up running alongside cohort expansion.
-
2027–2028
Confirmatory studies and filing preparation
Plan confirmatory studies in sequence and prepare the submission package in parallel with ongoing follow-up.
-
Q4 2027 or H1 2028
Target marketing application filing
Target submission of a U.S. marketing application to the FDA.
Sponsor planning targets. Sequence and timing depend on study results and required regulatory reviews.
CVM INAD I-014155
United States · Veterinary
The veterinary program is exploring intratumoral research in companion animals with spontaneous solid tumors, including dogs and cats. Study design and veterinary collaborations are in development.
Pet oncologyCVM receipt date for the INAD opening submission
Documented development milestone
Submitted the expanded conditional approval (XCA) eligibility request. The CVM portal shows that the center sent a response.
Documented development milestone
Submitted target animal safety (TAS) materials for chlorine dioxide injection in dogs and cats. The CVM portal shows that the center sent a response.
Investigational development
2027 U.S. veterinary development roadmap
China drug IND
China · Human
WanBinCell is preparing the requested supplementary dossier materials. Beijing Hospital is the planned research institution.
Application-material supplementation notice dated
Documented development milestone
Supplementary dossier package prepared
Application supplementation
China clinical development timeline
The U.S. and China programs advance in parallel. Enrollment, follow-up and preparation for the next stage are planned together to maintain continuity.
200+Cumulative enrollment target
-
2026–2027
Phase 1 start-up and early enrollment
Advance the China IND pathway and site start-up, then begin enrollment under the applicable protocol.
-
2027
Sequential enrollment and expansion
Continue the China development program toward at least 200 cumulative participants, with follow-up running alongside cohort expansion.
-
2027–2028
Confirmatory studies and filing preparation
Plan confirmatory studies in sequence and prepare the submission package in parallel with ongoing follow-up.
-
Q4 2027 or H1 2028
Target marketing application filing
Target submission of a marketing application in China on the same schedule.
Sponsor planning targets. Sequence and timing depend on study results and required regulatory reviews.
What an IND reference means
An investigational new drug (IND) application concerns use of an investigational drug in a proposed clinical investigation. IND 184255 identifies the CDX-101 regulatory file. Receipt, an effective IND, ethics approval, site activation and marketing authorization are separate milestones.
FDA IND procedures